TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02715167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00470210
Drug: Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
Study: NCT00017628
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01444508
Drug: Ringer-lactate SAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.
Study: NCT01631604
Drug: Muscle/nerve injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection to muscle or nerve
Study: NCT01444508
Drug: HES 130/04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate SAD.
Study: NCT00646581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02205528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
Study: NCT02993029
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib capsule 200mg qd by mouth.
Study: NCT02205528
Drug: NNC0090-2746
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
Study: NCT01224366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01796665
Drug: Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01796665
Drug: Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01707082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 0 mg, every 8 hours, 14 days
Study: NCT02600429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is composed of the same excipients as RGN-259 but does not contain Tβ4
Study: NCT01182870
Drug: choleclaciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800-6000 IU cholecalciferol per day
Study: NCT01707082
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 0 mg, every 8 or 12 hours, 14 days
Study: NCT03605914
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
Study: NCT02007252
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACZ885 150 mg liquid pre-filled syringes were administered s.c..
Study: NCT02007252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo liquid pre-filled syringes were administered s.c..
Study: NCT02206685
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
Study: NCT03299387
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
Study: NCT04296162
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine chemotherapy (oral)
Study: NCT03393949
Drug: Methylprednisolone 1 mg•kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Group M received methylprednisolone 1mg•kg-1
Study: NCT03393949
Drug: isotonic saline 1mg•kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Group C received isotonic saline 1mg•kg-1
Study: NCT01620762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose every 4 weeks
Study: NCT00304811
Drug: Vancomycin plus Gentamicin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00304811
Drug: Vancomycin plus Gentamicin plus Rifampin
Normalized name: betamethasone / clotrimazole / gentamicin Otic Ointment [Vetaderm Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02949271
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03640221
Drug: Hydrochlorothiazide 12.5mg
Normalized name: HYDROCHLOROTHIAZIDE 12.5MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator arm allow us to mimic the mild anti hypertensive effect seen with the SGLT-2 inhibitors in order to enable us to differentiate whether the cardiovascular protection seen with the SGLT-2 inhibitors is secondary to its antihypertensive effects vs the potential decrease in sympathetics.
Study: NCT00823901
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
Study: NCT01369511
Drug: LY2495655
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT01369511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT00227981
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04322422
Drug: Inhaled corticosteriod/long-acting beta-agonist only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma
Study: NCT01554592
Drug: Withdrawal of statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants currently received statin therapy will have their statin stopped for 12 weeks.
Study: NCT01554592
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will continue on stable statin therapy.
Study: NCT01841827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01257503
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid made to look like the active homeopathic remedy
Study: NCT02256787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02141347
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 administered intravenously.
Study: NCT03043066
Drug: scaling and root planing along with antibiotic intervention
Normalized name: dendropanax dentiger root with stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects underwent full mouth supragingival and subgingival scaling along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
Study: NCT00003311
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003311
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00227747
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00410995
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04454567
Drug: ABI-H0731
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ABI-H0731 tablets orally once daily
Study: NCT04454567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo to ABI-H0731 tablets orally once daily
Study: NCT04454567
Drug: NrtI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert
Study: NCT00699335
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
Study: NCT01887353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
Study: NCT01939639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal application, sodium chloride solution, 3 puffs per nostril
Study: NCT02463825
Drug: Placebo (Lactose tablet)
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03952806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00710827
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)
Study: NCT01888835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01809379
Drug: chemotherapy with doxorubicin and cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraperitoneal chemotherapy applied as an aerosol and under pressure
Study: NCT02136420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04162366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet, oral use once daily
Study: NCT01596907
Drug: Ephedrine sulfate with caffeine
Normalized name: Ephedrine Sulfate
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.
Study: NCT01839149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01456780
Drug: Loteprednol/tobramycin
Normalized name: LOTEPREDNOL/TOBRAMYCIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
Study: NCT03548987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (under the skin) injection of semaglutide placebo once-weekly.
Study: NCT02195557
Drug: Synvisc®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01885364
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection with normal saline before injection of propofol
Study: NCT01885364
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
Study: NCT02361138
Drug: SHR3824
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02361138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02886988
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1mlof normal saline will be injected with a 30G needle.
Study: NCT02416674
Drug: Immunosuppressive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.
Study: NCT00621647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00846391
Drug: MK8245 5 mg (twice a day) b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening.
Study: NCT00846391
Drug: MK8245 50 mg b.i.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening.
Study: NCT00846391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening.
Study: NCT00361309
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
Study: NCT00820027
Drug: Etoricoxib 90 mg
Normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 90 mg tablet once daily
Study: NCT00820027
Drug: Etoricoxib 120 mg
Normalized name: etoricoxib 120 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 60 mg tablets once daily
Study: NCT00820027
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One tablet three times daily
Study: NCT00820027
Drug: Matching Placebo for Etoricoxib 120 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets once daily
Study: NCT00820027
Drug: Matching Placebo for Etoricoxib 90 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet once daily
Study: NCT00820027
Drug: Matching Placebo for Ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet three times daily
Study: NCT02796820
Drug: Huaier Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaier Granule is continuously taken three times per day, 20g per time.
Study: NCT03821610
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT04255069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
Study: NCT04255069
Drug: Dose 1 JKB-122
Approvals — FDA: no, EMA: no, PMDA: no
Description: A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
Study: NCT04255069
Drug: Dose 2 JKB-122
Approvals — FDA: no, EMA: no, PMDA: no
Description: A treatment with dose 1 JKB-122, dose 2 JKB-122 or placebo will be randomly administrated once daily
Study: NCT04311619
Drug: [11C]UCB-J radiotracer
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein per injection
Study: NCT01500668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
Study: NCT01266135
Drug: QAX576
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAX576 10 mg/kg intravenous infusion
Study: NCT01266135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to QAX576 intravenous infusion
Study: NCT00336414
Drug: cyclophosphamide-prednisone-azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01534195
Drug: Prednisolone Sodium Phosphate Ophthalmic Solution 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in each eye, four times/day for 8 days.
Study: NCT01534195
Drug: Tears Naturale II Ophthalmic Solution
Normalized name: Tears Naturale Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop in each eye, four times/ day (QID) for 8 days
Study: NCT02356289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00272610
Drug: 0.4% Retinol Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00635882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF/F MDI placebo twice daily (BID) (2 inhalations)
Study: NCT01340573
Drug: PegIntron Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
Study: NCT00403728
Drug: ciclosporine A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01100775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
Study: NCT02182570
Drug: WAL 801 CL dry syrup
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02302404
Drug: GSK2982772 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
Study: NCT02302404
Drug: GSK2982772 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg
Study: NCT02302404
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
Study: NCT04325620
Drug: HIP1601
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIP1601
Study: NCT04325620
Drug: HGP1805
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of HIP1601
Study: NCT01998308
Drug: Crespine gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 Knees will have single injection of Crespine gel
Study: NCT03888820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
Study: NCT01998308
Drug: Intragel
Normalized name: TITANIUM DIOXIDE 63 mg in 1 mL / ZINC OXIDE 40 mg in 1 mL TOPICAL LOTION [INTRAL SENSITIVE SKIN ENVIRONMENTAL LIGHTWEIGHT SHIELD BROAD SPECTRUM SPF50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 Knees will have single injection of 2 ampules of Intragel
Study: NCT01998308
Drug: Crespine plus gel
Normalized name: Quest Plus Oral Gel Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 Knees will have single injection of Crespine Plus Gel
Study: NCT02302404
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Size 00 White Opaque capsule containing Placebo as white to almost white solid
Study: NCT02498496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 100 mL of Normal Saline
Study: NCT00956462
Drug: Ketorolac (NSAID) versus Dexamethasone (steroid)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical NSAID versus topical steroid after implantation of glaucoma drainage device
Study: NCT02629289
Drug: US-approved Neulasta
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02629289
Drug: EU-approved Neulasta
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00176462
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study: NCT00176462
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Study: NCT00176462
Drug: Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00176462
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01453608
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Placebo (saline) intravenously on Day 0
Study: NCT00010881
Drug: antioxidants
Normalized name: E Complex with Antioxidants
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00863291
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in a manner similar to the active comparator
Study: NCT01714401
Drug: Salbutamol 2,5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 min nebulization of 2.5 mg of salbutamol
Study: NCT00196872
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is given
Study: NCT00196872
Drug: Ibandronat
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronat is given
Study: NCT01809184
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo adminstered corresponding to insulin 287 treatment
Study: NCT02335125
Drug: Psychotropic Drugs
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01937325
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: active arm
Study: NCT00147355
Drug: ondansetron, ibuprofen, paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Study: NCT00147355
Drug: Ondansetron, ibuprofen, paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Study: NCT00147355
Drug: metoclopramide, ibuprofen, paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Study: NCT00147355
Drug: Metoclopramide, codeine phosphate, ibuprofen, paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Study: NCT00652860
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02042196
Drug: Placebo transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive transdermal patch